Limits...
Verification of tomotherapy dose delivery.

Pelagade SM, Paliwal BR - J Med Phys (2009)

Bottom Line: The agreement in absolute point dose was 1.19 +/- 0.79%, 1.91 +/- 1.39%, 2.14 +/- 1.3%, 1.3 +/- 0.73% and 1.67 +/- 1.5% for head and neck, prostate, pelvis-abdomen sites, and for all other sites.The spatial agreement between the calculated and the measured film dose distributions was evaluated using the gamma metric distribution.The average frequency versus gamma interval was plotted as a bar graph to quantify the gamma index variation inside the region of interest for each body site.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Physics, The Gujarat Cancer & Research Institute, NCH Campus, Asarwa, Ahmedabad-380016, India.

ABSTRACT
Seventy-one patient-specific delivery quality assurance (DQA) plans for the Tomotherapy HI-ART II helical tomotherapy system (TomoTherapy, Inc., Madison, WI, USA) were measured using film and ion chamber. The agreement in absolute point dose was 1.19 +/- 0.79%, 1.91 +/- 1.39%, 2.14 +/- 1.3%, 1.3 +/- 0.73% and 1.67 +/- 1.5% for head and neck, prostate, pelvis-abdomen sites, and for all other sites. The spatial agreement between the calculated and the measured film dose distributions was evaluated using the gamma metric distribution. The average frequency versus gamma interval was plotted as a bar graph to quantify the gamma index variation inside the region of interest for each body site.

No MeSH data available.


% Dose difference (absolute) variation for all 71 Cases
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2807687&req=5

Figure 0002: % Dose difference (absolute) variation for all 71 Cases

Mentions: The absolute percentage difference for the point dose measurements for different body sites is plotted in Figure 2. The average percentage dose difference and standard deviation for the set of cases evaluated for each body site were: 1.19±0.79% for head and neck, 1.91±1.39% for prostate, 2.14±1.3% for lung, 1.3±0.73% for abdomen and pelvis and 1.67±1.5% for other sites. The much larger standard deviation is noted for prostate, lung and other sites. This may be due to dose gradient at that point.


Verification of tomotherapy dose delivery.

Pelagade SM, Paliwal BR - J Med Phys (2009)

% Dose difference (absolute) variation for all 71 Cases
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2807687&req=5

Figure 0002: % Dose difference (absolute) variation for all 71 Cases
Mentions: The absolute percentage difference for the point dose measurements for different body sites is plotted in Figure 2. The average percentage dose difference and standard deviation for the set of cases evaluated for each body site were: 1.19±0.79% for head and neck, 1.91±1.39% for prostate, 2.14±1.3% for lung, 1.3±0.73% for abdomen and pelvis and 1.67±1.5% for other sites. The much larger standard deviation is noted for prostate, lung and other sites. This may be due to dose gradient at that point.

Bottom Line: The agreement in absolute point dose was 1.19 +/- 0.79%, 1.91 +/- 1.39%, 2.14 +/- 1.3%, 1.3 +/- 0.73% and 1.67 +/- 1.5% for head and neck, prostate, pelvis-abdomen sites, and for all other sites.The spatial agreement between the calculated and the measured film dose distributions was evaluated using the gamma metric distribution.The average frequency versus gamma interval was plotted as a bar graph to quantify the gamma index variation inside the region of interest for each body site.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Physics, The Gujarat Cancer & Research Institute, NCH Campus, Asarwa, Ahmedabad-380016, India.

ABSTRACT
Seventy-one patient-specific delivery quality assurance (DQA) plans for the Tomotherapy HI-ART II helical tomotherapy system (TomoTherapy, Inc., Madison, WI, USA) were measured using film and ion chamber. The agreement in absolute point dose was 1.19 +/- 0.79%, 1.91 +/- 1.39%, 2.14 +/- 1.3%, 1.3 +/- 0.73% and 1.67 +/- 1.5% for head and neck, prostate, pelvis-abdomen sites, and for all other sites. The spatial agreement between the calculated and the measured film dose distributions was evaluated using the gamma metric distribution. The average frequency versus gamma interval was plotted as a bar graph to quantify the gamma index variation inside the region of interest for each body site.

No MeSH data available.